{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T17:02:22Z","timestamp":1726419742952},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ijcard.2017.03.066","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T16:30:50Z","timestamp":1489854650000},"page":"22-24","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Drugs to prevent sudden cardiac death"],"prefix":"10.1016","volume":"237","author":[{"given":"Julia W.","family":"Erath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2017.03.066_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Sudden death in heart failure trail (SCD-HeFT) investigators, amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial","volume":"362","author":"Mc Murray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.03.066_bb0020","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0025","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0035","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0045","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/eurheartj\/ehs005","article-title":"Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials","volume":"33","author":"Rahimi","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0050","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency Bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.03.066_bb0060","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in-congestive heart failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.03.066_bb0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/joim.12141","article-title":"The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF","volume":"275","author":"Wikstrand","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0070","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","volume":"321","author":"Cardiac Arrhythmia Suppression Trial (CAST) Investigators","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0075","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(96)08171-8","article-title":"Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT","volume":"349","author":"Cairns","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2017.03.066_bb0080","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/eurheartj\/ehp100","article-title":"Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials","volume":"30","author":"Piccini","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2017.03.066_bb0095","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","article-title":"Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol implantable cardioverter-defibrillator study group","volume":"340","author":"Pacifico","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2017.03.066_bb0100","doi-asserted-by":"crossref","unstructured":"P. Dorian, M. Borggrefe, H. R. Al-Khalidi, et al. The SHock inhibition evaluation with azimiLiDe (SHIELD) investigators, placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator, Circulation 110 (2004) 3646\u201354.","DOI":"10.1161\/01.CIR.0000149240.98971.A8"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317314833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527317314833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T18:56:34Z","timestamp":1568919394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527317314833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":20,"alternative-id":["S0167527317314833"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.03.066","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs to prevent sudden cardiac death","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2017.03.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}